Morningstar

Saol Therapeutics Has Been Granted a Type A Meeting with the FDA to Determine the Path Forward for SL1009 in Pyruvate Dehydrogenase Complex Deficiency (PDCD)

FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...
EurekAlert!

ING5 inhibits aerobic glycolysis of lung cancer cells by promoting TIE1-mediated phosphorylation of pyruvate dehydrogenase kinase 1 at Y163

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis being the primary contributor to poor patient outcomes. A critical factor in ...
WZZM

Families plead with FDA to approve rare disease treatment

GRAND RAPIDS, Mich. — For families of children with pyruvate dehydrogenase complex deficiency (PDCD), a rare metabolic disorder, hope is tied to one drug: DCA. The treatment is given orally and works ...
JSTOR Daily

Efficient Coupling of Catalysis and Dynamics in the E1 Component of Escherichia coli Pyruvate Dehydrogenase Multienzyme Complex

Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 4 (Jan. 29, 2008), pp. 1158-1163 (6 pages) Protein motions are ubiquitous and are intrinsically coupled ...
Medscape

Not So Rare: Errors of Metabolism During the Neonatal Period

Metabolic acidosis is defined as a low pH (<7.35) due to an excess of acid (H +)oradeficit of base (HCO 3-). This occurs when there is an increased production of fixed or nonvolatile acids with a ...
Monthly Prescribing Reference

Mitapivat Granted Priority Review for Pyruvate Kinase Deficiency

Credit: Shutterstock. Mitapivat is a first-in-class, oral, selective small molecule allosteric activator of pyruvate kinase-R enzymes. The Food and Drug Administration (FDA) has accepted for Priority ...